The company SGS Institut Fresenius Diagnostiklabor GmbH was established in collaboration with the pathology laboratory Dr. Obrist – Dr. Brunhuber. The new laboratory focuses on analytics for personalised medicine from liquid biopsy (i.e., blood). Personalised medicine is mainly used in the initial diagnosis of tumour and cancer diseases and for assessing the course of treatment. Moreover, the laboratory also offers SARS-CoV-2-PCR tests analytics, especially for companies which want to regularly check their workforce until the pandemic has been contained as well as for event organisers aiming to secure their events.
The SGS Institute Fresenius ranks among the leading providers of non-medical laboratory analysis in Europe. It is part of the SGS Group, the world's leading company in examination, testing, verification and certification. Founded in 1878 and headquartered in Geneva, SGS has more than 89,000 employees and an international network of more than 2,600 branches and laboratories across the globe.
Continue reading and learn more about the successes in cancer research at the University of Innsbruck!